Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. develops Alpha DaRT, an intratumoral alpha-radiation therapy being studied for solid tumors. News about DRTS centers on clinical development, regulatory interactions and scientific presentations for Alpha DaRT across oncology programs including recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, and head and neck cancer.
Company updates frequently cover trial data, feasibility and safety findings, patient enrollment milestones, FDA device-pathway activity, conference abstracts and global study expansion. The news also reflects the company's focus on localized alpha-emitter radiation intended to treat tumors while limiting exposure to surrounding tissue.
Alpha Tau (NASDAQ: DRTS) reported Q1 2026 results and major clinical milestones for its Alpha DaRT cancer therapy.
Highlights include 100% local disease control in interim U.S. GBM and pancreatic trials, full enrollment of the pivotal U.S. ReSTART cSCC trial, FDA IDE expansion of the IMPACT pancreatic study, and $80.2 million in cash and deposits.
Alpha Tau (NASDAQ:DRTS) announced that CFO Raphi Levy will participate in several May 2026 investor conferences, including events hosted by H.C. Wainwright, Rothschild & Co Redburn, and Lytham Partners.
The schedule features fireside chats, presentations, and 1x1 investor meetings in New York and via virtual webcast.
Alpha Tau (Nasdaq: DRTS) reported interim data from the U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma. Three patients have been treated so far.
According to Alpha Tau, 100% local disease control was observed, with a 67% complete response rate, favorable safety and one resolved grade 3 SAE.
Alpha Tau Medical (Nasdaq: DRTS) will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. REGAIN trial for recurrent glioblastoma (GBM).
An archived webcast will be available after the event and investors may access the live stream via the company webcast link.
Alpha Tau (NASDAQ: DRTS) completed enrollment of 88 patients in its ReSTART U.S. pivotal trial evaluating Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC) on May 8, 2026. The company has initiated a modular PMA submission and holds FDA Breakthrough Device Designation for this indication.
The single-arm, multicenter study will move into follow-up to assess co-primary endpoints: objective response rate and six-month duration of response, plus secondary survival and quality-of-life measures. The program builds on prior international skin cancer studies treating hundreds of tumors.
Alpha Tau (Nasdaq: DRTS) announced on May 7, 2026 that the first patient in Italy was treated with Alpha DaRT for locally advanced pancreatic cancer at the University of Verona Pancreas Institute. The feasibility/safety protocol permits both EUS-guided and percutaneous delivery, expanding physician access and joining concurrent trials in France and the U.S.
The single-session, image-guided insertion targets patients who received prior chemotherapy or are unfit for systemic therapy; no efficacy or survival data were reported.
Alpha Tau (Nasdaq: DRTS) announced that top-line data from a clinical study of Alpha DaRT in combination with pembrolizumab for elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma will be presented as a podium paper at AHNS, July 21, 2026 in Boston.
The abstract reports complete top-line results from Hadassah Medical Center and highlights prior monotherapy safety data across the US, Europe, Israel, and Japan; no numeric efficacy or safety figures are included in this announcement.
Alpha Tau (Nasdaq: DRTS) reported pooled results from two first-in-human Alpha DaRT pancreatic cancer trials presented at DDW 2026. Across 19 evaluable patients the pooled analysis showed 100% local disease control (15 stable disease, 4 partial responses). Of 26 treated subjects, 8 device-associated adverse events occurred in 7 patients (27%), nearly all resolving within two weeks. The therapy was delivered via a streamlined outpatient EUS-guided procedure. Results were presented from Hadassah Medical Center and support advancement into the ongoing U.S. multicenter IMPACT trial.
Alpha Tau (Nasdaq: DRTS) announced that an abstract titled “Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer” was accepted to the 2026 ASCO Annual Meeting (May 29–June 2, 2026).
The pooled analysis combines safety and efficacy data from 58 patients across three prospective EUS-guided intratumoral Alpha DaRT studies at centers in Montreal and Jerusalem. The abstract will be published on the ASCO website on May 21, 2026 at 5:00 PM ET. Alpha Tau said this acceptance, alongside ASCO GI and DDW presentations, reflects growing scientific interest in its pancreatic program.
Alpha Tau (NASDAQ: DRTS) announced FDA approval of an IDE supplement to expand its U.S. IMPACT pancreatic cancer pilot trial. The supplement adds 10 patients receiving gemcitabine/nab-paclitaxel and increases total trial size from 30 to 40 patients. Recruitment completion shifts from Q2 to Q3 2026 to allow site approvals and added enrollment.